Jefferies is out with its report today on Incyte INCY, maintaining Buy.
In a note to clients, Jefferies writes, "While there were no major presentations for INCY's INCB28050 at EULAR, we note positive feedback from rheumatologists and new incremental details from the ORAL Solo Phase 3 study of tofacitinib. We remain confident in the commercial opportunity for 050 in rheumatoid arthritis."
Jefferies maintains a $25 PT on INCY.
Shares of INCY closed Friday at $17.92, up 2.52% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in